Sichuan Biokin Launches on HKEX, Raises HK$3.3 B in $389/Share Offering – A Milestone for China’s Biotech
China’s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced its successful initial public offering (IPO)...
Deals
AmacaThera Signs Exclusive Global License with Pacira BioSciences for AMT‑143, Up to $230 M Deal
AmacaThera, the hydrogel‑technology biotech incubated by Viva BioInnovator (VBI), announced an exclusive worldwide licensing agreement...
XtalPi’s Ailux Strikes $345 Million Partnership with Eli Lilly to Co‑Develop Bispecific Antibodies
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) disclosed that its wholly‑owned subsidiary Ailux...
HBM’s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co‑Develop In‑Vivo CAR‑T Platforms
HBM Holdings Limited (HKG: 2142) announced that its wholly‑owned subsidiary Nona Biosciences (Suzhou) Co., Ltd....
Shandong Jincheng Pharma Subsidiary Jincheng Taier to Sell Proxyl Vaginal Capsule Tech & MAH Rights to Shanghai Hemony for RMB 50 M
Shandong Jincheng Pharmaceutical Group Co., Ltd. (SHE: 300233) disclosed that its wholly‑owned subsidiary Jincheng Taier...
Baheal Pharma Locks CSL Behring Albumin Rights to Boost China’s Blood Product Supply
Baheal Pharma Group (SHE: 301015), a prominent Chinese therapeutic manufacturer, announced an enhanced cooperation agreement...
Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused
Prelude Therapeutics (NASDAQ: PRLD) unveiled a suite of strategic shifts: it signed an option deal...
4D Molecular Transfers Asia‑Pacific Gene‑Therapy Rights to Otsuka for $85 M Cash
4D Molecular Therapeutics (4DMT) sold the Asia‑Pacific rights to its eye‑gene therapy 4D‑150 to Otsuka...
MSD Secures Full Global Rights to MK‑8690 After $150 Million Settlement with Falk Pharma
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK), through its 2023 acquisition of Prometheus BioSciences,...
Metsera Faces Escalating Bidding War as Novo Nordisk’s $10 B Offer Tops Pfizer’s Revised Proposal
Biotech‑focused Metsera (NASDAQ: MTSR) announced that Novo Nordisk (NYSE: NVO) has submitted a “superior” acquisition...
Roche Announces a $55 M Partnership with Manifold Bio to Build BBB Shuttles
Swiss‑listed pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) confirmed a strategic alliance with platform biotech...
Sanyou Biopharmaceuticals and Liferiver Bio-Tech Forge Automation‑Driven Alliance to Accelerate Biologic Development
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Shanghai Liferiver Bio-Tech Co., Ltd. (SHA: 688317) inked a...
TransThera Sciences and Neurocrine Biosciences Ink $881.5 M NLRP3 Collaboration
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced today that it has entered into a royalty‑bearing patent‑assignment...
Betta Pharma Secures Exclusive Greater‑China Rights to Gensciences’ Long‑Acting Factor VIII Therapy
Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced today the signing of a Strategic Cooperation Framework...
CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...
Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones
Lepu (Beijing) Medical Technology Co., Ltd. (SHE: 300003) announced that its wholly‑owned subsidiary Shanghai Minwei...
Boehringer Ingelheim Licenses Pre‑Clinical Small‑Molecule Program from Kyowa Kirin for Autoimmune Therapy
Boehringer Ingelheim announced a licensing deal to acquire exclusive worldwide rights to a promising first‑in‑class...
Chengdu Maxvax Secures Series D Financing at Over RMB 400 Million to Accelerate Shingles and RSV Vaccine Development
China‑based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series D funding round,...
BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing
BrightGene Bio‑Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of...
JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding
JW Therapeutics Ltd. (HKG: 2126) announced today the signing of a supplementary strategic cooperation agreement...